14321-27-8

Basic information

• Product Name: N-Ethylbenzylamine
• Synonyms: LABOTEST-BB LTBB000558;N-ETHYLBENZYLAMINE;NEBA;N-BENZYLETHYLAMINE;Benzylamine, N-ethyl-;Benzylethylamine;Ethylbenzylamine;N-Benzyl-N-ethylamine
• CAS NO: 14321-27-8
• Molecular Formula: C₉H₁₃N
• Molecular Weight: 135.21
• EINECS: 238-265-1
• Product Categories: Polyamines
• Mol File: 14321-27-8.mol
• Article Data: 84

Chemical Properties

• Melting Point: 191-194
• Boiling Point: 191-194 °C(lit.)
• Flash Point: 152 °F
• Appearance: Clear colorless to slightly yellow/Liquid
• Density: 0.909 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.518mmHg at 25°C
• Refractive Index: n20/D 1.511(lit.)
• Storage Temp.: Store below +30°C.
• Solubility: slightly soluble
• PKA: 9.77±0.10(Predicted)
• Water Solubility: slightly soluble
• Sensitive: Air Sensitive
• BRN: 386023
• CAS DataBase Reference: N-Ethylbenzylamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Ethylbenzylamine(14321-27-8)
• EPA Substance Registry System: N-Ethylbenzylamine(14321-27-8)

Safety Data

• Hazard Codes: C
• Statements: 34-37-52
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2735 8/PG 3
• WGK Germany: 3
• TSCA: Yes
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 14321-27-8(Hazardous Substances Data)

Usage

Description

N-Ethylbenzylamine is an organic compound that exists as a clear colorless to slightly yellow liquid. It is characterized by its reactivity and is commonly utilized in various chemical processes and applications due to its unique properties.

Uses

Used in Chemical Synthesis:
N-Ethylbenzylamine is used as a reagent for the synthesis of various organic compounds. Its reactivity with NDTE (2,5-dihydroxyphenylacetic acid, 2,5-bis-tetrahydropyranyl ether p-nitrophenyl ester) and HLTE (homogentisic gamma-lactone tetrahydropyranyl ether) demonstrates its utility in chemical reactions, particularly in the preparation of derivatives and complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-Ethylbenzylamine is used as a key intermediate in the synthesis of certain drugs and drug candidates. Its role in preparing 2-[(N-Benzyl, N-ethyl)amino]derivative using 2-chloro-4H-pyrido[1,2-a]pyrimidin-4-one highlights its importance in the development of novel therapeutic agents.
Used in Research and Development:
N-Ethylbenzylamine is also employed in research and development settings, where its reactivity and properties are studied to understand its potential applications in creating new materials, chemicals, and pharmaceuticals. Its clear colorless to slightly yellow liquid form makes it suitable for various experimental procedures and analyses.

Synthesis Reference(s)

Chemistry Letters, 15, p. 917, 1986Journal of the American Chemical Society, 91, p. 3996, 1969 DOI: 10.1021/ja01042a078Tetrahedron Letters, 9, p. 61, 1968

InChI:InChI=1/C9H13N/c1-2-10-8-9-6-4-3-5-7-9/h3-7,10H,2,8H2,1H3/p+1

Upstream product

• 588-46-5 N-(phenylmethyl)acetamide 
• 6852-54-6 N-(benzylidene)ethylamine 
• 34233-75-5 N-ethylidenebenzylamine 
• 25566-56-7 N-benzyl-N-ethyl-4-methylbenzenesulfonamide 
• 860695-07-4 2-(ethyl-benzyl-sulfamoyl)-benzoic acid 
• 557-66-4 ethanamine hydrochloride 
• 100-52-7 benzaldehyde 
• 75-04-7 ethylamine 
• 75-07-0 acetaldehyde 
• 100-44-7 benzyl chloride 
• 100-46-9 benzylamine 
• 74-96-4 ethyl bromide 
• 60-29-7 diethyl ether 
• 4788-37-8 N-ethyl-N-methylbenzylamine 

Downstream Products

• 91339-47-8 N-benzyl-2-(ethylamino)ethanol 
• 107418-17-7 ethyl-benzyl-(2-[4]pyridyl-ethyl)-amine 
• 218900-28-8 N-(tert-butoxycarbonyl)-N-benzylethylamine 
• 305856-65-9 tert-butyl carbonic N-benzylethyl carbamic anhydride 
• 861709-19-5 C₁₈H₁₉F₂NO 

Relevant articles and documents

-

-

Synthesis and evaluation of Zn(II) dithiocarbamate complexes as potential antibacterial, antibiofilm, and antitumor agents

Four complexes having the formula [Zn(L)2] [L1 = (C18H20NS2 –), N-(4-isopropyl-benzyl)-(benzyl)-dithiocarbamate], [L2 = (C10H12NS2 –), N-(benzyl)-(ethyl)-dithiocarbamate], [L3 = (C19H22ONS2 –), N-(4-isopropyl-benzyl)-(4-methoxy-benzyl)-dithiocarbamate], and [L4 = (C16H16NS2 –), N-(benzyl)-(4-methyl-benzyl)-dithiocarbamate] have been contemplated, synthesized, and characterized by elemental analysis and IR, 1H, 13C NMR and UV–visible absorption spectra. All Zn(II) complexes have similar geometry and coordination number. Complex A2 (with ligand L2) crystallizes in triclinic system with space group P-1 having distorted square pyramidal geometry which was stabilized by weak C–H···π and C–H···S intramolecular interactions. The antibacterial, antibiofilm, and antitumor activities of the complexes have been screened and A2 and A3 showed their prominence. Interestingly, both A2 and A3 showed more killing potential against multi-drug resistant gram-positive isolates with MIC indices of 16 μg mL?1 and 16 μg mL?1, respectively, against both MRSA and MSSA, while the antitumor agent A3 showed its prominence with GI50 and LC50 41.15 and 133.73 μg mL?1, respectively.

Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease

A novel series of dimethylamino chalcone-O-alkylamines derivatives was designed and synthesized as multifunctional agents for the treatment of AD. All the target compounds exhibited significant abilities to inhibit and disaggregate Aβ aggregation, and acted as potential selective AChE inhibitors, biometal chelators and selective MAO-B inhibitors. Among these compounds, compound TM-6 showed the greatest inhibitory activity against self-induced Aβ aggregation (IC50 = 0.88 μM) and well disaggregation ability toward self-induced Aβ aggregation (95.1%, 25 μM), the TEM images, molecular docking study and molecular dynamics simulations provided reasonable explanation for its high efficiency, and it was also found to be a remarkable antioxidant (ORAC-FL values of 2.1eq.), the best AChE inhibitor (IC50 = 0.13 μM) and MAO-B inhibitor (IC50 = 1.0 μM), as well as a good neuroprotectant. UV–visual spectrometry and ThT fluorescence assay revealed that compound TM-6 was not only a good biometal chelator by inhibiting Cu2+-induced Aβ aggregation (95.3%, 25 μM) but also could disassemble the well-structured Aβ fibrils (88.1%, 25 μM). Further, TM-6 could cross the blood-brain barrier (BBB) in vitro. More importantly, compound TM-6 did not show any acute toxicity in mice at doses of up to 1000 mg/kg and improved scopolamine-induced memory impairment. Taken together, these data indicated that TM-6, an excellent balanced multifunctional inhibitor, was a potential lead compound for the treatment of AD.

Method for preparing amine compound by reducing amide compound

The invention relates to a method for preparing an amine compound by reducing an amide compound, which comprises the following steps: in a protective atmosphere, mixing the amide compound or cyclic amide, a zirconium metal catalyst and pinacol borane, carrying out amide reduction reaction at room temperature, and carrying out aftertreatment by using an ether solution of hydrogen chloride after 12-48 hours to obtain an amine hydrochloride compound. The method is simple to operate, low in cost, good in functional group tolerance and wide in substrate range.

Deoxygenative hydroboration of primary, secondary, and tertiary amides: Catalyst-free synthesis of various substituted amines

Transformation of relatively less reactive functional groups under catalyst-free conditions is an interesting aspect and requires a typical protocol. Herein, we report the synthesis of various primary, secondary, and tertiary amines through hydroboration of amides using pinacolborane under catalyst-free and solvent-free conditions. The deoxygenative hydroboration of primary and secondary amides proceeded with excellent conversions. The comparatively less reactive tertiary amides were also converted to the corresponding N,N-diamines in moderate yields under catalyst-free conditions, although alcohols were obtained as a minor product.